BioSpace News Archive

Editas Medicine, Inc., a clinical stage genome editing company, announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK gene editing technology.

Femasys Inc. (NASDAQ: FEMY) today announced that the Company’s management team will be attending the annual Conference for the American Society for Colposcopy and Cervical Pathology (ASCCP) held May 4 -7, 2023 at the Marriott Marquis in Houston.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) has presented the foundational preclinical data that supported the initial clinical development of its novel serotonin-dopamine stabilizer brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) in San Diego.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis (FSGS).

Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced it will host a key opinion leader webinar on May 8, 2023 at 11:00 a.m. ET.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023.

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2023 financial results after market close on Monday, May 8, 2023.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023.

Hologic, Inc. announced the Company’s financial results for the fiscal second quarter ended April 1, 2023.